1. Volume 68, Issue 4, Pages 570-577 (October 2015)
Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration- resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302 
Fred Saad, Neal Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas A. Griffin, Peter De Porre, Anil Londhe, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan 
European Urology 
Volume 68, Issue 4, Pages (October 2015)
DOI: /j.eururo
Copyright © 2015 European Association of Urology Terms and Conditions

2. Fig. 1
Kaplan-Meier estimates of (A) overall survival, (B) time to opiate use for cancer-related pain, and (C) time to deterioration in Eastern Cooperative Oncology Group performance status (ECOG PS) score by ≥1 point. AA=abiraterone acetate; BTT=bone-targeted therapy; CI=confidence interval; NE=not estimable; P=prednisone.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions